优先接种Heplisav-B疫苗的成本-效用评估
本研究评估了在美国推荐接种乙肝疫苗的成人人群中,使用两剂Heplisav-B相比三剂Engerix-B的成本-效用。通过决策树模型和马尔可夫疾病进展模拟,发现除无应答者外,Heplisav-B在所有人群中均减少HBV感染、后遗症和死亡,并降低成本或增加收益,对糖尿病、慢性肾病、肥胖、HIV、老年人和注射吸毒者具有成本节约优势。
要点
- Heplisav-B在多数推荐接种人群中可减少HBV感染和后遗症。
- 对无应答者,Heplisav-B增加成本且收益有限。
- 在HIV和注射吸毒者中,Heplisav-B系列效力≥80%时始终成本更低且收益更高。
核心结论
- 对糖尿病、慢性肾病、肥胖、HIV成人、老年人和注射吸毒者,Heplisav-B相比Engerix-B是成本节约策略。
研究设计与样本
- 采用决策树模型结合微观模拟和马尔可夫疾病进展过程,评估Heplisav-B对比Engerix-B的成本-效用。
- 分析人群包括糖尿病、肥胖、慢性肾病、HIV成人、既往乙肝疫苗无应答者、老年人和注射吸毒者。
主要发现
- 基础情景下,Heplisav-B减少HBV感染37.5-59.8%,减少后遗症和HBV相关死亡36.3-71.4%。
- 除无应答者外,Heplisav-B降低成本并增加收益;增量成本从节省4746.78美元(注射吸毒者)到增加14.15美元(无应答者)。
- 每人增量收益从0.00005 QALYs(老年人)到0.7 QALYs(注射吸毒者)。
关键数值与推荐
- Heplisav-B每剂115.75美元,Engerix-B每剂57.25美元(2019年6月1日价格)。
- 对HIV感染者和注射吸毒者,当Heplisav-B系列效力至少80%时,所有情景下均成本更低且收益更高。
临床怎么用
- 优先为糖尿病、慢性肾病、肥胖、HIV成人、老年人和注射吸毒者接种Heplisav-B以节约成本。
- 对既往乙肝疫苗无应答者,需权衡Heplisav-B的额外成本与有限收益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is the primary strategy to prevent hepatitis B virus (HBV) infection in the United States. Prior to 2017, most standard hepatitis B vaccine schedules required 3 doses over 6 months. Heplisav-B, approved in 2017, is administered in 2 doses over a 1 month time period but has a higher per-dose cost ($115.75 per dose compared to $57.25 per Engerix-B dose, costs as of June 1, 2019). We aimed to assess the cost-utility of providing the two-dose Heplisav-B vaccine compared to a three-dose Engerix-B vaccine among adult populations currently recommended for vaccination against hepatitis B. We used a decision-tree model with microsimulation and a Markov disease progression process to assess the cost-utility separately for the following populations: adults with diabetes, obesity, chronic kidney disease, HIV; non-responders to previous hepatitis B vaccination; older adults; and persons who inject drugs (PWID). We modeled epidemiologic outcomes (incident HBV infections, sequelae and related deaths), costs (2019 USD) and benefits (quality-adjusted life years, QALYs) and compared them across strategies. Sensitivity analyses assessed the cost-utility at varying estimates of Heplisav-B efficacy. In the base case scenario for each population, vaccination with Heplisav-B resulted in fewer HBV infections (37.5-59.8% averted), sequelae, and HBV-related deaths (36.3-71.4% averted). Heplisav-B resulted in decreased costs and increased benefits compared to Engerix-B for all populations except non-responders. Incremental costs from the baseline strategy ranged from $4746.78 saved (PWID) to $14.15 added cost (non-responders). Incremental benefits per person ranged from 0.00005 QALYs (older adults) to 0.7 QALYs (PWID). For persons with HIV and PWID, Heplisav-B resulted in lower costs and increased benefits in all scenarios in which Heplisav-B series efficacy was at least 80%. Vaccination using Heplisav-B is a cost-saving strategy compared to Engerix-B for adults with diabetes, chronic kidney disease, obesity, and HIV; older adults; and PWID.
引用
- Rosenthal EM, Hall EW, Rosenberg ES, et al. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations. Vaccine. 2020. PMID: 33160756. doi:10.1016/j.vaccine.2020.10.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。